No Data
No Data
Chordia Therapeutics: Financial results presentation materials for the fiscal year ending 2024/8
Chordia---Research and development of pipelines centered around CTX-712 for the fiscal year ending in August 2024 is progressing smoothly.
Chordia Therapeutics <190A> announced its financial results for the August 2024 period on the 11th. Operating revenue was N/A (business revenue of 2.5 billion yen in the previous period), operating loss was 1.801 billion yen (profit of 0.212 billion yen in the same period), ordinary loss was 1.824 billion yen (profit of 0.225 billion yen in the same period), and net loss for the period was 1.827 billion yen (profit of 0.223 billion yen in the same period). In the current fiscal year, the pipeline is centered around the CLK inhibitor drug CTX-712 (hereinafter referred to as CTX-712).
Chordia Therapeutics --- Announced the results of the Phase 1 clinical trial of CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology
Chordia Therapeutics <190A> announced the analysis results of the first phase clinical trial of the CLK inhibitor CTX-712 in Japan, targeting 14 blood cancer patients at the 86th Annual Meeting of the Japanese Society of Hematology on the 11th. This presentation is not significantly different from the content presented by the company at the American Association for Cancer Research Annual Meeting in April 2024, but the analysis was re-conducted based on data as of July 5, 2024, and the results were reported for the first time in Japan.
Chordia Reports Phase 1 Trial Results for CLK Inhibitor at Hematology Conference
Stocks that moved the previous day part1 include Shochiku, AeroEdge, Koshidaka HD, etc.
Stock name <Code> 11th closing price ⇒ Previous day comparison Shochiku <9601> 9246 -106925 Financial estimates for the fiscal year ending February 25 have been revised downward. Vitz <4440> 840 +30 Operating profit is expected to increase by 50.6% in the previous period and 19.6% in this period. Part-time Thai <2341> 143 -8 The operating profit for the first half decreased by 98.2%, expanding the decrease rate from 80.3% in the first quarter. Chordia <190A> 296 -38 At the Japan Society of Hematology Academic Meeting, the first-phase clinical trial of the CLK inhibitor CTX-712.
Active and newly established stocks in the afternoon session.
*Matsushita <9601> 9246 -106 Lowered financial estimates for the fiscal year ending February 2025. *Vitz <4440> 840 +30 Operating profit expected to increase by 50.6% from the previous period and by 19.6% for the current period. *Albaitai <2341> 143 -8 The operating profit for the first half decreased by 98.2%, expanding the decrease rate from 80.3% in the first quarter. *Chordia <190A> 296 -38 Announcement of the results of the Phase I clinical trial of the CLK inhibitor CTX-712 at the Japan Society of Hematology Annual Meeting. *Aer
No Data
No Data